N-Acetylcysteine

Clinical Summary

N-Acetylcysteine is the acetylated derivative of the amino acid Cysteine, serving as the most clinically validated precursor for Glutathione (GSH) synthesis. The acetyl group enhances oral stability while preserving the free thiol (-SH) group responsible for its antioxidant, mucolytic, and glutamate-modulating activities.

NAC occupies a rare position in the supplement world: FDA-approved drug AND widely available supplement, with 648+ registered clinical trials on ClinicalTrials.gov and Cochrane-level evidence for several indications. Its strongest evidence is in emergency medicine (acetaminophen overdose antidote, >95% efficacy) and respiratory disease (COPD exacerbation prevention, Cochrane RR 0.77). Moderate evidence supports psychiatric applications (OCD, trichotillomania, addiction) and metabolic conditions (PCOS, metabolic syndrome).

Oral bioavailability is low (11.6% average) but clinically effective because hepatic first-pass extraction delivers NAC directly to the liver — actually beneficial for hepatoprotective indications. Low cost ($10-20/month), excellent safety profile at standard doses, and decades of clinical use make it one of the best risk-reward supplements available.

Key mechanisms: (1) Glutathione precursor — cysteine is rate-limiting for GSH synthesis; (2) Direct thiol antioxidant — scavenges ROS/RNS immediately; (3) Mucolytic — cleaves disulfide bonds in mucus glycoproteins; (4) Glutamate modulator — regulates system xc⁻ cystine-glutamate antiporter in brain; (5) NF-κB inhibitor — indirect anti-inflammatory via ROS reduction; (6) AMPK activator — insulin-sensitizing effects.

2025-2026 update: 28 new meta-analyses published since last review. Key developments include gut microbiota-dependent bioavailability mechanism (PMID 40389439, Nature Communications), NAC amide (NACA) emerging as superior derivative, ferroptosis modulation as new mechanism, and a Phase 3 trial for retinitis pigmentosa (NCT, PMID 41282901). A preclinical study raised concern about NAC facilitating breast cancer metastasis via neutrophil reprogramming (PMID 41516400) — preclinical only, but notable.

Indications & Evidence

Reading this table: Stars = evidence volume/quality. Type = causal relationship (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star rating legend: 5/5=Multiple large RCTs + meta-analyses | 4/5=Several human RCTs or extensive human data | 3/5=Some human pilot/limited RCT | 2/5=Animal or very limited human | 1/5=Theoretical/debunked

Prescribing

Dosing Table

Formulation Table

Condition-Specific Protocols

COPD / Bronchiectasis Exacerbation Prevention

Evidence: 5/5 (COPD) / 4/5 (bronchiectasis) | Key PMIDs: 31107966 (Cochrane), 40180519 (RIBRON)

Phase 1: Initiation (Weeks 1-4)

• 600 mg once daily with breakfast
• Goal: assess GI tolerance before dose escalation
• Monitor: GI symptoms, baseline spirometry

Phase 2: Therapeutic (Weeks 5-52)

• 600 mg BID (1200 mg/day) — evidence-supported dose
• Continue all inhaled medications (LABA/LAMA/ICS)
• Monitor: exacerbation frequency, sputum volume, antibiotic courses

Phase 3: Maintenance (Year 1+)

• Continue 1200 mg/day indefinitely during high-risk seasons or year-round for severe disease
• Reassess annually: if <2 exacerbations/year, consider step-down to 600 mg/day

Expected Outcomes: 23% reduction in exacerbations (NNT 7-10); 59.7% sputum reduction in bronchiectasis; 12% Pseudomonas reduction. Greater benefit in patients NOT on inhaled corticosteroids. Stop/Reassess: If no exacerbation reduction after 12 months at full dose.

OCD / Trichotillomania (Adjunct)

Evidence: 4/5 | Key PMIDs: 39376972 (OCD MA), 34582562 (Cochrane TTM)

Phase 1: Initiation (Weeks 1-2)

• 600 mg BID (1200 mg/day)
• Continue SSRI + CBT/ERP; NAC is augmentation, not replacement
• Monitor: Y-BOCS or MGH-HPS baseline score

Phase 2: Therapeutic (Weeks 3-16)

• If tolerated, increase to 1200 mg BID (2400 mg/day) at week 3
• Expect onset of benefit at weeks 8-12 (glutamate modulation is slow)
• Monitor: Y-BOCS q4 weeks; subjective compulsive urge frequency

Phase 3: Maintenance (Week 16+)

• If responding (≥25% Y-BOCS reduction): continue at effective dose long-term
• If no response by week 16: unlikely to benefit; discontinue

Expected Outcomes: 45-55% response rate for OCD (d=0.52); 56% for TTM in landmark study. Evening dosing may better align with peak glutamatergic dysregulation. Stop/Reassess: No improvement by 16 weeks = discontinue.

PCOS (Ovulation + Metabolic)

Evidence: 4/5 | Key PMID: 39861414 (2025 MA)

Phase 1: Initiation (Weeks 1-2)

• 600 mg once daily with dinner
• Baseline labs: fasting glucose, insulin (HOMA-IR), testosterone, LH/FSH, lipids

Phase 2: Therapeutic (Weeks 3-24)

• 600 mg TID with meals (1800 mg/day total)
• If fertility goal: combine with Clomiphene (NAC may enhance ovulation induction)
• Monitor: menstrual regularity, ovulation tracking, HOMA-IR at 3 months

Phase 3: Maintenance (Month 6+)

• If ovulating: continue until pregnancy or reassess at 6 months
• If metabolic-only goal: continue 1800 mg/day; recheck HOMA-IR, lipids, testosterone

Expected Outcomes: ~50% relative increase in ovulation rate (RR 1.52); 41% relative increase in clinical pregnancy; improved insulin sensitivity. May be comparable to Metformin for some PCOS outcomes. Drug Interaction Timing: If also on Metformin, both cause GI upset — start NAC at 600 mg/day ×2 weeks before escalating.

Safety

Interactions Table

Contraindications

• Severe allergy/anaphylactoid reaction to NAC (3-6% incidence with IV; rare with oral)
• Concurrent nitroglycerin/nitrate therapy (without BP monitoring)
• Severe renal impairment (GFR <30): reduce dose to 600 mg every other day or avoid
• Active peptic ulcer disease (theoretical mucolytic effect on gastric mucus)
• Caution in active cancer treatment: preclinical data (PMID 41516400, 2026) suggests NAC may facilitate breast cancer metastasis via neutrophil reprogramming — mechanism is preclinical but warrants discussion with oncologist before supplementing during active cancer therapy

Adverse Effects (ranked by frequency)

1. GI distress (nausea, bloating, diarrhea, gas) — 30-40% at doses >1200 mg; dose-dependent; mitigated by food
2. Sulfur burps / body odor — 15-20%; thiol metabolism byproduct; worse at higher doses
3. Anaphylactoid reaction (IV only) — 3-6%; rash, pruritus, bronchospasm; slow infusion rate to prevent
4. Headache — occasional; more common with IV
5. Anhedonia / emotional blunting — reported in ~5-10% of community users; biologically plausible via glutamate modulation of reward circuits; not well-documented in clinical literature; reversible on discontinuation
6. Histamine reactions — NAC inhibits DAO ~20%, may trigger reactions in histamine-intolerant individuals
7. Dry eyes — multiple community reports; mechanism unclear

FAERS Signal Table (from BioMCP)

Reading FAERS data: Total 10,477 reports. The vast majority relate to IV acetylcysteine in hospital settings (overdose treatment, CIN prophylaxis, ICU) — NOT oral supplementation. Top reactions (dyspnoea, pneumonia, AKI) reflect acutely ill populations receiving IV NAC. GI effects (nausea, vomiting, diarrhoea) are the only signals relevant to oral supplementation. No new unexpected safety signals identified in FAERS for oral use.

Monitoring Table

Special Populations

Renal Impairment

Pregnancy & Lactation

• FDA Pregnancy Category B — no teratogenicity in animal studies at 10x human dose
• Acetaminophen OD in pregnancy: NAC is standard of care (IV preferred; crosses placenta to protect fetus)
• Routine supplementation: NOT recommended — insufficient safety data
• PCOS fertility context: Small studies suggest safety at 600 mg/day during conception attempts
• Lactation: Unknown excretion in breast milk; avoid unless medically indicated
• Alternative: Dietary cysteine from protein (chicken, eggs, dairy, legumes)

Synergies & Stacking

Antagonisms:

• Activated-Charcoal: physical adsorption reduces NAC absorption 30-50%
• High-dose antioxidant stacks during exercise: may blunt training adaptations (theoretical for NAC; demonstrated for vitamin C+E)

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

No dedicated NAC pharmacogenomics studies exist as of 2026. This remains a major evidence gap. The above are mechanistic extrapolations from variant-pathway knowledge, not NAC-specific clinical data.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Moderately positive (mixed) across ~1000+ reports. NAC is considered a "solid workhorse" — reliable but not dramatic.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: LOW. One case identified (Elomir "Axis Klarrity" strips — founder had SEC fraud settlement). NAC itself is generic, cheap, and widely available from established brands. Not an MLM product.
• Influencer concentration: MODERATE. Huberman, Bryan Johnson (Blueprint), Thomas DeLauer drive traffic. But NAC enthusiasm is distributed across many independent voices — not concentrated in one person.
• Astroturfing signals: LOW. NAC is cheap (~$10-15/month), generic, sold by dozens of brands. No single company has strong astroturfing incentive.
• Commercial bias: MODERATE in practitioner space. Some naturopathic physicians who recommend NAC also sell branded NAC products (commercial conflict of interest).
• FDA regulatory drama: Generated "buy before it's banned" fear-marketing in 2020-2022. FDA reversed course; NAC remains available as supplement.

Folk vs Clinical Reality Check

Community experience aligns well with clinical data for respiratory (mucus clearance), OCD/compulsive behaviors (glutamate modulation), liver support, and immune function. Community reports of anhedonia/emotional blunting are biologically plausible (system xc⁻ modulation of reward circuits) and deserve clinical investigation — this is under-reported in the literature. The GlyNAC longevity hype is outrunning the evidence (single research group, small N). The "hangover cure" use is plausible (glutathione pre-loading for acetaldehyde metabolism) but unverified by RCT. The East Asian skin-brightening angle has partial support (cysteine inhibits melanin synthesis) but most evidence is for L-cysteine, not NAC specifically. The gray hair reversal claim is folk myth with essentially no clinical support.

Deep Dive: Mechanisms & Research

Core Mechanisms (with clinical translation status)

1. Glutathione Precursor (Clinical translation: YES) NAC is deacetylated in intestinal and hepatic cells to release Cysteine, the rate-limiting amino acid for GSH synthesis. The two-step ATP-dependent synthesis: (1) glutamate + cysteine → γ-glutamylcysteine (via GCL); (2) + Glycine → GSH (via glutathione synthetase). Normal intracellular GSH: 1-10 mM; liver highest at 5-10 mM. Depletion below 20-30% of normal triggers oxidative damage. This mechanism underlies the acetaminophen overdose indication directly.

2. Glutamate Modulation via System xc⁻ (Clinical translation: PARTIAL) System xc⁻ (cystine-glutamate antiporter) exchanges extracellular cystine for intracellular glutamate. NAC-derived cysteine/cystine modulates extrasynaptic glutamate → reduced presynaptic glutamate release → normalized glutamatergic neurotransmission. This underlies psychiatric applications (OCD, addiction, schizophrenia). Effect sizes are moderate (d=0.3-0.5) and not all patients respond, suggesting the mechanism is real but not sufficient for large clinical effects in all individuals.

3. NF-κB Inhibition (Clinical translation: PARTIAL) By reducing ROS, NAC indirectly inhibits NF-κB activation → reduced TNF-α, IL-1β, IL-6 expression. This mediates anti-inflammatory effects in RA (CRP reduction) and metabolic syndrome. Clinical effects are modest adjunctive benefits, not primary anti-inflammatory therapy.

4. AMPK Activation (Clinical translation: PARTIAL) NAC activates AMP-activated protein kinase → improved insulin sensitivity, increased fatty acid oxidation, reduced lipogenesis. This underlies PCOS and metabolic syndrome benefits. HOMA-IR reductions of 15-30% are clinically meaningful but not transformative.

5. Mucolytic Action (Clinical translation: YES) Thiol-disulfide exchange cleaves disulfide bonds in mucus glycoproteins, reducing viscosity. Direct mechanism → direct clinical effect in respiratory indications. COPD Cochrane evidence confirms this pathway.

6. Gut Microbiota-Dependent Absorption (NEW, 2025) Nature Communications (PMID 40389439): NAC intestinal permeability is driven by gut microbiota-dependent cysteine palmitoylation. This is a fundamentally new finding — the gut microbiome directly modulates NAC bioavailability. Implications: antibiotic use, dysbiosis, or probiotics may alter NAC efficacy. Not yet clinically integrated.

7. Ferroptosis Modulation (NEW, 2025-2026) NAC inhibits ferroptosis (iron-dependent cell death) in multiple models: intestinal epithelial cells (PMID 39037665), spinal cord injury (PMID 41270839). Conversely, iron supplementation switches APAP-induced cell death to ferroptosis, making it NAC-resistant (PMID 40518003). Clinical implication: iron co-administration may blunt NAC's hepatoprotective effect in overdose.

Pharmacokinetics

• Oral bioavailability: 11.6% (range 4-30%); dose-dependent — higher doses (>600 mg) show better bioavailability due to first-pass saturation (PMID 2328298)
• Tmax: 1-2 hours (oral); immediate (IV)
• Half-life: 5.58 hours (IV), 6.25 hours (oral) (PMID 3360052)
• Protein binding: 50-83% (albumin)
• Metabolism: Hepatic deacetylation (desired → cysteine), sulfoxidation (minor, inactive), gut bacterial metabolism to H₂S
• Elimination: Renal; clearance 0.19-0.28 L/h/kg
• Chinese PK data (PMID 41138059, 2026): Bioequivalence study in healthy Chinese volunteers confirms similar PK profile

NAC Amide (NACA) — Emerging Derivative

NACA (N-acetylcysteine amide) is gaining research attention as a potentially superior form (PMID 41953516, 2026 comprehensive review). Advantages: better oral bioavailability, improved blood-brain barrier penetration, neutral charge at physiological pH. Active research in: neovascularization (PMID 41240786), retinal protection (PMID 39251120), lens opacity (PMID 40149978), salivary gland radioprotection (PMID 40940999). Not yet commercially available as supplement; watch this space.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Total registered interventional trials: 648. Completed: 367. Currently recruiting: 45. NAC has one of the broadest clinical trial portfolios of any supplement.

Regulatory Status (from BioMCP)

• FDA: Approved as Rx drug (IV: Acetadote/generics for acetaminophen overdose; inhaled: mucolytic for bronchopulmonary disease/CF). Also available as OTC dietary supplement — FDA attempted to restrict supplement sales 2020-2022, reversed course.
• EMA: National-level approvals across EU (ACC, Fluimucil in Germany/Italy; Mucomyst in France). Predates EMA centralized procedure.
• WHO: Essential Medicines List (antidote category).
• Regulatory context: NAC's dual drug/supplement status is unique. FDA restriction attempt was commercial/regulatory, not safety-based.

Ataraxia Verdict (as of 2026-04-16)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to mechanism: NAC's molecular pathways (NF-κB, AMPK, system xc⁻, Nrf2) are described extensively in promotional content, often implying clinical benefit from pathway activation alone. Mechanism ≠ clinical outcome.
• Hasty generalization: GlyNAC protocol extrapolated from small Sekhar lab studies to broad anti-aging claims. The original file had a 10x glycine dosing error (1 g/kg/day instead of 100 mg/kg/day), suggesting uncritical propagation.
• Cherry-picking: Bronchiectasis was rated 5/5 from one observational registry — now corrected to 4/5.
• Appeal to popularity: "648 registered trials" and "millions of users" do not validate any specific indication.
• Survivorship bias: Community reports over-represent responders; the ~50% non-responder rate for psychiatric indications is under-discussed.

Evidence Gaps

• No long-term cardiovascular outcomes trial: Biomarker improvements (HOMA-IR, lipids, CRP) look good short-term; nobody has tested whether years of NAC prevent heart attacks or diabetes.
• No brain glutathione measurement studies at scale: Oral NAC's effect on brain GSH is assumed, not proven.
• No microbiome impact studies: The new gut microbiota-dependent absorption mechanism (PMID 40389439) is unstudied in chronic users.
• No sex-stratified dosing data: CYP differences are known; no NAC trial has powered for sex-based analysis.
• No pharmacogenomic studies: Despite plausible variant targets (SOD2, COMT, GST), no clinical data exists.
• Anhedonia mechanism: Community-reported emotional blunting at ~5-10% rate is biologically plausible but uncharacterized in controlled studies.

Bias Flags (Mode 4: First Principles)

• The compound's strongest evidence is where mechanism maps directly to clinical outcome: Overdose (GSH repletion → NAPQI detox), respiratory (mucolysis → sputum clearance). Where the chain is longer (mechanism → biomarker → presumed clinical benefit), evidence weakens.
• Psychiatric NAC trials suffer from classic "decline effect": Landmark small trials show large effects; larger replications show smaller effects. The true effect size for OCD/addiction is likely at the lower end of published ranges.
• "Not approved" ≠ "unsafe": NAC's supplement status reflects commercial/regulatory history, not safety concerns. The FDA restriction attempt was about drug exclusivity, not toxicology.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: Generic amino acid with many manufacturers; no single dominant player. Marketing is moderate — "glutathione booster" positioning is accurate but oversimplified.
• Influencer economics: Huberman, Bryan Johnson drive awareness. Affiliate links are common in YouTube/blog NAC content. However, NAC is too cheap for high-margin affiliate schemes.
• Counter-narrative manipulation: FDA's 2020-2022 restriction attempt generated conspiracy theories and "banned supplement" marketing. The restriction was bureaucratic (drug exclusivity precedent), not safety-driven.
• Cui bono summary: Pro-NAC: supplement companies (low margin but high volume), anti-aging clinics, biohacker influencers. Anti-NAC: pharmaceutical mucolytic competitors (ambroxol/erdosteine), psychiatric drug makers (SSRIs), CIN debunkers (hydration-only advocates). Neither side has overwhelming financial incentive.
• Red team highlight: The exercise adaptation concern (antioxidants blunting training benefits) is the most legitimate risk for the target audience of biohackers and fitness-focused individuals. NAC-specific data is limited, but the mechanism is plausible.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 8/10 — foundational antioxidant with broad utility across respiratory, immune, liver, psychiatric, and metabolic domains; FDA-approved drug status, WHO Essential Medicine, Cochrane-level evidence for multiple indications, and an exceptional safety/cost profile.
• Opportunity cost: Very low — $10-20/month, minimal interactions, low side effect burden, reversible
• Verdict: ADD
• Rationale: Strong evidence for core indications (respiratory, hepatoprotective), moderate for psychiatric/metabolic, excellent safety profile, very low cost. The risk-reward ratio is among the best in the supplement world. Not a miracle — but a solid, well-evidenced foundation compound.

Bottom Line

NAC is one of the rare supplements where marketing claims are less dramatic than the actual evidence base. It has FDA drug approval, WHO Essential Medicines status, 648 registered trials, and Cochrane-level evidence for multiple indications. Its biggest weakness is low oral bioavailability, which is partially offset by hepatic first-pass delivery. Psychiatric benefits are real but modest and inconsistent across individuals. Metabolic benefits are biomarker-level, not outcomes-level. The compound is cheap, safe, and well-understood. For someone interested in foundational health optimization, NAC is a straightforward add — not because it's transformative, but because it's reliable and the downside is negligible.

Practical Notes

Brands & Product Selection

• Quality markers: USP/NSF verified, third-party tested (ConsumerLab, Labdoor), no proprietary blends
• Established brands: NOW Foods (most studied; common in Japanese/Korean markets), Jarrow Formulas, Life Extension, Thorne
• Red flags: "Clinical strength" marketing without citing specific dose; proprietary NAC blends with undisclosed amounts; MLM products (Elomir)
• CoA requirement: Request Certificate of Analysis for heavy metal testing (lead, arsenic, mercury, cadmium)
• Form preference: Standard 600 mg capsules for most users; effervescent for GI-sensitive; avoid powder (sulfur taste/odor)

Storage & Handling

• Store in cool, dry place; NAC is hygroscopic and degrades with moisture
• Shelf life: 2-3 years in sealed container; less once opened
• Degradation indicators: Strong sulfur smell from bottle (beyond normal mild thiol odor), color change (white → yellow/brown), powder clumping
• Do not store near strong oxidizers
• Refrigeration not required but extends potency in humid climates

Palatability & Compliance

• Capsules: preferred for most; swallow whole to avoid sulfur taste
• Powder: strong sulfur/egg taste; mix with citrus juice or flavored water
• Effervescent: better taste; slight cost premium
• Compliance tip: Pair with existing habit (morning coffee, meal). The #1 determinant of supplement efficacy is whether you actually take it consistently.

Exercise & Circadian Timing

• Pre-workout caution: High-dose antioxidants may blunt exercise adaptations (mitochondrial biogenesis, PGC-1α activation). NAC-specific data is limited but mechanistically plausible.
• Recommendation for athletes: Avoid chronic daily NAC during adaptation-focused training blocks. Use during competition/recovery phases. Post-workout (within 2h) is reasonable for recovery.
• Morning dosing: Best for respiratory conditions, general antioxidant support
• Evening dosing: May better align with peak glutamatergic dysregulation for psychiatric indications (anecdotal; not rigorously studied)
• Split dosing: For >1200 mg/day, divide BID or TID to minimize GI effects

Reference Ranges (Expected Biomarker Changes)

Cost

• Standard dose (600 mg/day): $0.15-0.30/day = $5-10/month
• Therapeutic dose (1200 mg/day): $0.30-0.60/day = $10-20/month
• High dose (1800 mg/day): $0.45-0.90/day = $15-30/month
• GlyNAC stack: Add ~$10-15/month for glycine
• Cost-effectiveness: Excellent. Among the cheapest evidence-backed supplements available.

What We Don't Know

• Whether long-term NAC supplementation prevents cardiovascular events (only biomarker data exists)
• Whether oral NAC meaningfully increases brain glutathione levels (MRS studies are few and small)
• How the gut microbiome modulates NAC bioavailability in chronic users (PMID 40389439 opens this question)
• Whether sex-specific dosing would improve outcomes (CYP differences known; no stratified trials)
• Whether pharmacogenomic variants (SOD2, COMT, GST) meaningfully alter clinical response (no data)
• The mechanism and prevalence of NAC-induced anhedonia reported by ~5-10% of community users
• Whether NAC's preclinical breast cancer metastasis facilitation (PMID 41516400) translates to humans
• Whether NACA (NAC amide) is genuinely superior in clinical outcomes, not just PK parameters
• Long-term effects on trace mineral status (zinc, copper) with chronic use
• Whether the "hangover prevention" folk use has any clinical basis
• Optimal cycling protocols for athletes who want recovery benefits without blunting adaptations
• Independent replication of the GlyNAC aging protocol outside the Sekhar lab

References

Meta-Analyses & Systematic Reviews

• PMID 31107966 — Poole et al. (2019) Cochrane: Mucolytic agents vs placebo for COPD. NAC reduces exacerbations RR 0.77.
• PMID 39376972 — (2024) SR+MA: NAC augmentation in adult OCD. Updated effect size d=0.52.
• PMID 34582562 — Hoffman et al. (2021) Cochrane: Pharmacotherapy for trichotillomania. NAC included.
• PMID 39861414 — Vina et al. (2025) SR+MA: NAC efficacy in PCOS. RR 1.52 ovulation.
• PMID 39556483 — Winterlind et al. (2024) MA: NAC for substance use cravings.
• PMID 39504621 — Peng et al. (2024) Updated SR+MA: NAC for depression. Mostly negative.
• PMID 37712506 — (2024) SR+MA: NAC acceptability + efficacy for psychotic disorders. d=0.36 negative symptoms.
• PMID 39618229 — (2024) SR+MA: NAC as adjuvant therapy for RA. CRP -3.2 mg/L.
• PMID 38842239 — (2025) SR+MA: NAC reducing postoperative AF in cardiothoracic surgery.
• PMID 39139444 — (2024) SR+MA: NAC for post-CABG AF prevention.
• PMID 38467037 — (2024) SR+MA: NAC to reduce mortality in cardiac catheterization/surgery.
• PMID 41312470 — (2025) MA: Saline + NAC strategies for contrast-associated AKI.
• PMID 40728675 — (2025) MA: NAC on mortality in COVID-19.
• PMID 40418545 — (2025) MA (GRADE): NAC + COVID-19 outcomes.
• PMID 40323204 — (2025) SR+MA: NAC prevention of cisplatin-induced hearing loss.
• PMID 39905500 — (2025) SR+MA: Intratympanic NAC for cisplatin ototoxicity.
• PMID 40126496 — (2025) SR+MA: NAC to improve seminal parameters.
• PMID 40350672 — (2025) MA: L-carnitine vs NAC for male infertility.
• PMID 41188701 — (2025) SR+MA: NAC for preventing post-ERCP pancreatitis.
• PMID 41977262 — (2026) SR: NAC across 7 neurological disorders.
• PMID 41874704 — (2026) SR: NAC + glutathione in Parkinson's disease.
• PMID 41812482 — (2026) MA: Interventions for trichotillomania (updated).
• PMID 38555190 — (2024) Distinct MAs: NAC in COPD vs chronic bronchitis/pre-COPD.
• PMID 39632267 — (2024) SR+MA: NAC impact on lactate, oxidative stress, immune response, muscle damage.
• PMID 39309000 — (2024) MA: NAC for craving in substance use disorders.
• PMID 39493366 — (2024) SR: NAC impact on airway mucus hypersecretion.
• PMID 39101362 — (2024) SR+MA: NAC after liver resection.
• PMID 41977015 — (2026) SR: NAC in thrombotic thrombocytopenic purpura.
• PMID 40013897 — Nakatsu et al. (2025) MA: Two-bag vs three-bag NAC for paracetamol.
• PMID 30975143 — (2019) Bronchiectasis RCT.

Landmark RCTs & Key Studies

• PMID 38197864 — Acetaminophen overdose management (2024 update).
• PMID 2328298 — NAC pharmacokinetics (dose-dependent bioavailability).
• PMID 3360052 — NAC half-life determination (IV and oral).
• PMID 21890206 — IV NAC protocol for acetaminophen overdose.
• PMID 16207100 — NAC systematic review for CIN prevention.
• PMID 21126198 — NAC efficacy in acetaminophen toxicity.
• PMID 33380301 — Sekhar et al. GlyNAC in aging (glycine + NAC protocol).
• PMID 40180519 — (2025) RIBRON registry: NAC in bronchiectasis (N=2461).
• PMID 40421021 — (2025) RCT: Vitamin D + NAC for immunosenescence in older adults.
• PMID 41016625 — (2025) RCT: NAC for adolescent/young adult alcohol use disorder.
• PMID 40875537 — (2025) Double-blind RCT: NAC for PTSD + alcohol use disorder.
• PMID 41486713 — (2025) RCT: Fluoxetine vs NAC for alcohol craving.
• PMID 40163249 — (2025) JAMA Neurol: NAC for hereditary cystatin C amyloid angiopathy.
• PMID 39112288 — (2024) RCT: NAC FAILED for facial melasma (negative).
• PMID 38470079 — (2024) RCT: Microneedling + NAC for vitiligo.
• PMID 41234378 — (2025) Pilot: Oral NAC + NB-UVB for vitiligo.
• PMID 39360368 — (2024) RCT: NAC for dry eye in Sjogren's disease.
• PMID 38284479 — (2024) Crossover pilot: NAC for thiopurine-induced liver injury in IBD.
• PMID 41577060 — (2026) RCT: NAC reduces linezolid-associated thrombocytopenia.

Mechanism & Preclinical

• PMID 40389439 — (2025) Nature Communications: Gut microbiota-dependent cysteine palmitoylation modulates NAC absorption.
• PMID 41953516 — (2026) Comprehensive review: NAC as thiol-based modulator + NACA advantages.
• PMID 41516400 — (2026) CAUTION: NAC facilitates breast cancer metastasis via neutrophil reprogramming (preclinical).
• PMID 40518003 — (2025) Iron switches APAP cell death to ferroptosis, rendering NAC-resistant.
• PMID 39037665 — (2025) NAC inhibits ferroptosis in necrotizing enterocolitis.
• PMID 40362589 — (2025) NAC attenuates Aβ-mediated oxidative stress in 5xFAD mice.
• PMID 41619526 — (2026) NAC changes functional brain connectivity in Parkinson's.
• PMID 41579736 — (2026) White matter burden predicts cognitive response to NAC + exercise in vascular MCI.
• PMID 40414419 — (2025) Review: NAC neuroprotection via glutamate modulation + synaptic plasticity.
• PMID 40235406 — (2025) NAC enhances fracture healing in rat femoral diaphysis.
• PMID 34171332 — H₂S and sulfane sulfur species from gut NAC metabolism.
• PMID 36312742 — (2022) Review: Principles behind SLE treatment with NAC.
• PMID 41282901 — (2025) NAC Attack Phase 3 trial protocol for retinitis pigmentosa.

Guidelines & Cochrane

• PMID 26957510 — ACMT Position Statement: IV NAC duration for acetaminophen overdose.
• PMID 17709050 — ACEP Clinical Policy: Acetaminophen overdose management.
• PMID 37690008 — Canadian Thoracic Society (2023): Pharmacotherapy in stable COPD.
• PMID 24559602 — Canadian Association of Radiologists: CIN prevention guidelines.
• PMID 32532534 — Mexican Consensus: Alcoholic hepatitis (NAC as adjunct).
• PMID 39497389 — Chinese TB Guidelines (2024): Anti-TB drug-induced liver injury.
• PMID 32900213 — Lee et al. (2021) MA: NAC in ASD.
• PMID 30725868 — StatPearls: NAC monograph (updated 2026).

East Asian Research

• PMID 41138059 — (2026, China) PK/bioequivalence of NAC in healthy Chinese volunteers.
• PMID 41207540 — (2025, Japan) Molecular hydrogen + NAC synergy for APAP liver injury.
• PMID 41456031 — (2025, Korea) NAC termination cut-off values in paracetamol poisoning.
• PMID 41546041 — (2025, Taiwan) NAC + D-methionine for noise-induced hearing loss.
• PMID 41383104 — (2025, Korea) NAC restores dentate gyrus neurogenesis in neonatal maternal separation.
• PMID 40774821 — (2025, Korea) NAC protection against oxLDL-induced endothelial dysfunction.
• PMID 41312470 — (2025, Taiwan) MA: NAC for contrast-associated AKI prevention.